Key TakeawaysSubstantiating outcome claims before publication is non-negotiable: agencies must maintain a claim-review workflow and evidence file, since FTC liability for objective claims runs to the advertiser, not the agency 1.MAT and prescription-drug creative triggers FDA OPDP obligations for fair balance, so a named reviewer and risk-disclosure workflow must exist before any branded medication reference ships 3.Clinician-featured and alumni testimonial creative carries AMA truthfulness standards and...
Key TakeawaysAgencies that treat every past-patient list as remarketing fuel misread HIPAA’s marketing rule; written authorization must precede any use of PHI outside narrow exceptions 1, 3.Lead-gen pools, paid directories, and affiliate arrangements involving patient data trigger HIPAA’s remuneration provisions, so require the agency to map each payment flow to authorization language 2.Pixels, chat widgets, and session-replay scripts on authenticated or care-linked pages must comply with...
Key TakeawaysTreat agency selection as a clinical-adjacent decision because paid visibility measurably shifts how patients and referrers perceive care quality, independent of any clinical change 1.Verify regulatory posture through operational artifacts—executed BAAs, PHI data-flow diagrams, and substantiation workflows—rather than accepting stated HIPAA, FTC, and CMS familiarity at face value 6, 5, 3.Test evidence discipline by requesting a redacted substantiation file from a live account, since FTC...
Key TakeawaysDelegating pixel and consent decisions to IT exposes centers to FTC enforcement; marketing contracts should specify approved tags, consent states, and data flows before launch.Outcome and success-rate claims require competent and reliable scientific evidence on file before running, so require a substantiation log covering population, instrument, and measurement window 14.Micro-targeting people in acute crisis with urgency triggers crosses ethical lines flagged in peer-reviewed research;...
Key TakeawaysOutcome guarantees without defined methodology, follow-up windows, and sample sizes trigger FTC substantiation exposure; qualified partners build claims from clinical evidence before copy is drafted 1.Uploading CRM exports, alumni lists, or treatment-episode data into ad platforms crosses the HIPAA marketing line unless mapped to a Privacy Rule exception or written authorization 9.SUD records under 42 CFR Part 2 require consent naming the specific recipient and purpose; hashing does not...
Key TakeawaysTreat compliance as a performance input by mapping HHS OCR, FTC, SAMHSA, and 42 CFR Part 2 obligations to the same marketing artifacts an agency produces 2, 8.Vet for behavioral health specifics, not general healthcare experience, because Part 2 imposes consent and redisclosure rules that sit on top of HIPAA and reshape intake and testimonial workflows 9.Require a signed BAA and a documented authorization workflow before any PHI-derived list, CRM field, or call recording reaches ad audiences...
